Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-01-15Clinical Trial Update: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 trial results update for Vyxeos (CPX-351) in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes; results we…
-
CLINICAL_TRIALS trial_result · 2019-01-09Clinical Trial Update: A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating vadastuximab talirine administered before or after allogeneic stem cell transplant in acute myeloid leukemia; stu…
-
CLINICAL_TRIALS trial_result · 2019-01-08Clinical Trial Update: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant [Phase 2]
Phase II multicenter trial evaluating CD26 inhibition with sitagliptin for engraftment after umbilical cord blood transplant in hematologic …
-
CLINICAL_TRIALS trial_result · 2019-01-04Clinical Trial Update: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
Phase 2 results from a study using donor umbilical cord blood stem cell transplants in patients with hematologic malignancies have been post…
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia [Phase 3]
Phase 3 trial evaluating cytarabine and daunorubicin or idarubicin with or without vorinostat for younger patients with untreated acute myel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-12-12Clinical Trial Update: Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 3]
Phase 3 trial update for vadastuximab talirine combined with azacitidine or decitabine in older patients with newly diagnosed acute myeloid …
-
CLINICAL_TRIALS trial_result · 2018-12-11Clinical Trial Update: Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) [Phase 1, Phase 2]
Clinical trial update on panobinostat in combination with idarubicin and cytarabine in older adults with newly diagnosed acute myeloblastic …
-
CLINICAL_TRIALS trial_result · 2018-12-06Clinical Trial Update: A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response [Phase 2]
Phase II trial evaluating SGI-110 in patients with various high-risk myelodysplastic syndromes and related conditions not responding to prio…
-
CLINICAL_TRIALS trial_result · 2018-11-29Clinical Trial Update: Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy [Phase 1]
Phase 1 clinical trial evaluating a new anti-cancer immunotherapy in adults with acute myeloid leukemia who had suboptimal response to induc…
-
FDA approval · 2018-11-28FDA Approved: XOSPATA — Original Application (Astellas Pharma US, Inc.)
FDA approved XOSPATA (gilteritinib) as an original application for adult patients with relapsed or refractory FLT3-mutated acute myeloid leu…
-
FDA approval · 2018-11-21FDA Approved: DAURISMO — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved DAURISMO (glasdegib) from Pfizer as an original NDA for the treatment of adults with acute myeloid leukemia who are not candida…
-
CLINICAL_TRIALS trial_result · 2018-11-21Clinical Trial Update: Reduced Intensity Double Umbilical Cord Blood Transplantation [Phase 2]
Phase 2 results for reduced-intensity double umbilical cord blood transplantation were completed and results posted in 2018. The study evalu…
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). [Phase 1, Phase 2]
Clinical trial update on safety of oral azacitidine (CC-486) as maintenance therapy after allogeneic stem cell transplantation in AML or MDS…
-
CLINICAL_TRIALS trial_result · 2018-11-15Clinical Trial Update: SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update examining SGI-110 with donor lymphocyte infusions after allogeneic stem cell transplantation for myelodysplast…
-
CLINICAL_TRIALS trial_result · 2018-11-13Clinical Trial Update: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML [Phase 1]
A Phase 1 trial of metformin combined with cytarabine for relapsed/refractory acute myeloid leukemia was terminated, with results posted in …
-
CLINICAL_TRIALS trial_result · 2018-11-07Clinical Trial Update: Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating clofarabine plus cytarabine in previously untreated acute myeloid leukemia and high-risk myelodysplastic syndrome h…
-
CLINICAL_TRIALS trial_result · 2018-10-31Clinical Trial Update: Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]
A nonmyeloablative preparative regimen using Mylotarg (gemtuzumab ozogamicin) was studied in Phase 2/Phase 3 trials for high-risk acute myel…
-
FDA approval · 2018-10-22FDA Approved: AZACITIDINE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for azacitidine from BluePoint Laboratories, indicating an update to the drug's labeling or indicati…
-
CLINICAL_TRIALS trial_result · 2018-10-18Clinical Trial Update: Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) [Phase 1, Phase 2]
A clinical trial investigating sensitization of non-M3 acute myeloid leukemia blasts to all-trans retinoic acid using epigenetic treatment w…
-
CLINICAL_TRIALS trial_result · 2018-10-17Clinical Trial Update: A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS [Phase 2]
Phase 2 study evaluating multiple-dose, dose-escalation of AEB1102 in patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome has …
-
CLINICAL_TRIALS trial_result · 2018-10-17Clinical Trial Update: G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor [Phase 4]
A Phase 4 clinical trial evaluating G-CSF alone or in combination with GM-CSF for prevention and treatment of infection in children with mal…
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia [Phase 1]
Phase 1 study of LY573636-sodium in Acute Myeloid Leukemia and Essential Thrombocythemia completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-10-12Clinical Trial Update: DC Vaccination for Postremission Therapy in AML [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating dendritic cell vaccination as postremission therapy for acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2018-10-11Clinical Trial Update: Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML [Phase 2]
Phase II trial investigating alisertib in combination with induction chemotherapy for high-risk acute myeloid leukemia has completed with re…
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML [Phase 2, Phase 3]
Phase 2/3 trial investigating the effect of G-CSF on minimal residual disease after induction therapy in newly diagnosed acute myeloid leuke…